Showing 7071-7080 of 8887 results for "".
- Study: Newer Biologics Do Not Increase MACE/VTE Risk in PsO/PsAhttps://practicaldermatology.com/news/Study-Newer-Biologics-Do-Not-Increase-MACE-VTE-Risk-PsO-PsA/2471065/A new emulated target trial analysis found no significant risk differences in major adverse cardiovascular events (MACE) or venous thromboembolic events (VTE) in patients with psoriasis or psoriatic arthritis treated with IL-17, IL-12/23, or IL-23 inhibitors vs those treated with TNF inhibitors.<
- Study Shows Oral Minoxidil Improves Patient Outcomes for Hair Losshttps://practicaldermatology.com/news/study-shows-oral-minoxidil-improves-patient-outcomes-for-hair-loss/2471041/New research in the Journal of Drugs in Dermatology shows oral minoxidil outperforming topical formulations in terms of patient adherence, satisfaction, and ease of use, without significantly increasing systemic side effects. Researchers on the study studied 50 patients using eith
- Biologic Therapy in Psoriasis: Secukinumab and Ustekinumab Lead in Retentionhttps://practicaldermatology.com/news/biologic-therapy-in-psoriasis-secukinumab-and-ustekinumab-lead-in-retention/2471042/Switching patterns of biologics in psoriasis treatment revealed influences of gender and psoriatic arthritis (PsA), according to new research. The retrospective study from the nationwide digital prescription database of Greece has shed light on biologic treatment trends for psoriasis betwe
- Study: Safety Signals Emerge for IL-23 and IL-12/23 Inhibitors in Psoriasis Treatmenthttps://practicaldermatology.com/news/safety-signals-emerge-for-il-23-and-il-1223-inhibitors-in-psoriasis-treatment/2470971/A new analysis of psoriasis patients indicates an emergence of new safety signals associated with interleukin-23 (IL-23) inhibitors and the IL-12/23 inhibitor ustekinumab. Researchers on the study analyzed 41.4 million adverse event (AE) reports from the FDA Adverse Event Reporting System
- Gene Expression Patterns Linked to Psoriasis Severity and Treatment Responsehttps://practicaldermatology.com/news/gene-expression-patterns-linked-to-psoriasis-severity-and-treatment-response/2470916/Gene expression abnormalities not only reflect the severity of psoriatic lesions but also predict treatment response, according to a recent study published in JID Innovations. Researchers on the study analyzed gene expression profiles in psoriatic skin using Gene Set Variation Ana
- PPIs, H2RAs Can Increase Psoriasis Risk for Patients With GI Diseaseshttps://practicaldermatology.com/news/ppis-h2ras-can-increase-psoriasis-risk-patients-gi-diseases/2470871/Prolonged use of proton pump inhibitor (PPI) or histamine-2 receptor antagonists (H2RA) is associated with the risk of psoriasis among patients with gastrointestinal diseases, according to a new study published in the Korean Journal of Internal Medicine. The study included 3,662 p
- Higher WWI Linked to Increased Mortality Rates in Psoriasis Patientshttps://practicaldermatology.com/news/higher-wwi-linked-increased-mortality-rates-psoriasis-patients/2470869/New research indicates a strong positive correlation between weight-adjusted waist index (WWI) and all-cause mortality in psoriasis patients. Researchers at Wenzhou Medical University in China published “Weight-Adjusted Waist Index, Psoriasis, and All-Cause Mortality: Findings from the NHA
- Skin Cancer Foundation Names New Executive Directorhttps://practicaldermatology.com/news/skin-cancer-foundation-names-new-executive-director/2470856/The Skin Cancer Foundation (SCF), a national nonprofit organization that is committed to decreasing the incidence and mortality of the world’s most common cancer through public education, announced that it has appointed Becky Kamowitz to the role of executive director. Kamowitz has worked
- VYNE Therapeutics Completes Enrollment for Phase 2b Trial of VYN201 in Nonsegmental Vitiligohttps://practicaldermatology.com/news/vyne-therapeutics-completes-enrollment-phase-2b-trial-vyn201-nonsegmental-vitiligo/2470854/VYNE Therapeutics Inc. has finalized enrollment for its Phase 2b trial of VYN201, a once-daily topical gel for nonsegmental vitiligo, with initial data from the 24-week double-blind portion anticipated in mid-2025, according to a news release from the manufacturer. The randomized, double-b
- Genetic Study Reveals Psoriasis-Sudden Hearing Loss Connectionhttps://practicaldermatology.com/news/genetic-study-reveals-psoriasis-hearing-loss-connection/2470853/A recent genetic study has established a causal relationship between psoriasis and an elevated risk of sudden sensorineural hearing loss (SSNHL). Researchers derived the findings using Mendelian randomization (MR) analysis to identify potential connections between inflammatory skin disease